Skip to content

Psychiatric Multi-omics and Neuroimaging Project

Psychiatric Multi-omics and Neuroimaging Project Database

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06580860
Acronym
PMNP
Enrollment
1899
Registered
2024-08-30
Start date
2016-01-01
Completion date
2027-01-01
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Control, Mental Disorders

Keywords

schizophrenia, major depressive disorder, autism spectrum disorder, bipolar disorder, magnetic resonance imaging, multi-omics

Brief summary

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Detailed description

The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.

Interventions

DRUGAntipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Sponsors

mingjun Zhong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age) * Course of disease: \<24 months * Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * No nuclear magnetic contraindications.

Exclusion criteria

* Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * Have a major physical disease or infectious disease * History of coma and serious neurological disease 4.MRI contraindications.

Design outcomes

Primary

MeasureTime frameDescription
cortical morphology40 minutesData were obtained using magnetic resonance scans
target gene charaacteristics1 day10ml peripheral blood was extracted for gene analysis
scale scores90 minutes.The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.

Countries

China

Contacts

CONTACTYunzhi Pan
panyunzhi@csu.edu.cn15074818197

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026